Genotypic and functional properties of early infant HIV-1 envelopes

Retrovirology

Table 1 Clinical and laboratory status of study participants

Subject^a	Birth year	Sample timing	Plasma viral load (copies/ml)	CD4	CD8	CD4:CD8	No. of envclones	No. of pseudo viruses	ART status
M1003		0	14158	466	932	0.50	12	4	None
P1189	1994	31	311538	2872	1975	1.45	10	2	None
M1002		28	ND	872	1225	0.71	25	5	None
P1031	1992	54	685169	2147	927	2.32	11	3	None
M1001		2	26000	534	726	0.74	19	4	None
P1024	1990	51	750000	3312	4504	0.74	11	2	None
M1007		-8	ND	870	1176	0.74	22	4	ZDV
P1046	1995	66	1229730	2573	1693	1.52	22	4	ZDV*
M1006		-33	260541	134	403	0.33	20	5	ZDV
P1049	1999	30	647919	ND	ND	ND	10	2	ZDV*

^aM, Mother; P, Infant. ZDV, Zidovudine administered to mother or infant to prevent MTCT. ND, Not determined. Timing of samples used for cloning in days after delivery; negative numbers indicate days before delivery.

ISSN: 1742-4690